8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Regeneron says Q4 2025 will include an acquired IPR&D charge of ~ $19M pre-tax, reducing GAAP and non‑GAAP…
Filed with the SEC on · Summarized by InvestorsBot
Regeneron says Q4 2025 will include an acquired IPR&D charge of ~ $19M pre-tax, reducing GAAP and non‑GAAP diluted EPS by ~ $0.14. Preliminary estimate disclosed at J.P. Morgan (Jan 12). 🧾 $REGN #Regeneron #Biotech
Regeneron committed to match Good Days donations up to $200M for remainder of 2025; notified of ~ $60M in Q4 donations, resulting in a ~ $60M matching charge recorded to SG&A in Q4 2025. 💝 $REGN #Regeneron #Philanthropy
Regeneron’s Q4/FY2025 results are preliminary (unaudited), included in Exhibit 99.1, and subject to closing procedures—actual results may differ. Presented at the J.P. Morgan Healthcare Conf on Jan 12. ⚠️ $REGN #Earnings #Regeneron